Vigil Neuroscience EBIT

The latest EBIT for VIGL is $-97M as of June 2025. That compares with $-90M in the prior-year period — down 7.3% year over year. That is below the sector sector average of $-63M. Investors often review this figure alongside Vigil Neuroscience's historical trend and sector peers before judging valuation or financial health.

Over the past year, VIGL's EBIT moved from $-90M to $-97M — a 7.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vigil Neuroscience's operating scale or balance-sheet position.

Against its sector companies, VIGL currently prints $-97M for EBIT, while the sector average sits near $-63M. That is roughly 54.6% below the sector mean. Large gaps often invite a closer look at Vigil Neuroscience's growth, margins, and balance sheet.

A EBIT figure of $-97M for VIGL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting VIGL's EBIT ($-97M), review year-over-year change from $-90M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.